|
Variables
|
Male(n = 137)
|
Female(n = 177)
|
P value
|
|---|
|
Continuous variable (mean ± SD)a
|
|
Age (years)
|
73.12 ± 8.41
|
71.82 ± 7.49
|
0.148
|
|
Grip strength (kg)
|
33.86 ± 8.05
|
20.23 ± 5.26
|
< 0.001
|
|
SMI (ALM/ht2)(kg/m2)
|
7.26 ± 0.79
|
5.79 ± 0.66
|
< 0.001
|
|
Gait speed(m/s)
|
1.13 ± 0.34
|
1.09 ± 0.30
|
0.330
|
|
Number of comorbidity.
|
0.77 ± 0.93
|
0.76 ± 1.02
|
0.922
|
|
AGE(μg/mL)
|
37.65 ± 17.80
|
37.48 ± 16.45
|
0.933
|
|
RAGE(pg/ml)
|
1204.24 ± 496.12
|
1280.28 ± 568.82
|
0.236
|
|
Categorical variable (%)b
|
|
HTN
|
39.4%
|
31.1%
|
0.124
|
|
DM
|
10.9%
|
14.1%
|
0.403
|
|
MI
|
1.5%
|
0.6%
|
0.419
|
|
Angina
|
0.7%
|
1.1%
|
0.718
|
|
CAD
|
10.9%
|
5.1%
|
0.052
|
|
COPD
|
2.9%
|
5.6%
|
0.245
|
- Abbreviations: AGE Advanced glycation end products, sRAGE soluble receptor for advanced glycation end-products, SMI skeletal muscle mass index, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CAD coronary artery disease, COPD chronic obstructive pulmonary disease
- aValues in the continuous variables were expressed as mean and standard deviation
- bValues in the categorical variables were expressed in number and percentage (%)
- Pearson’s chi-square test was applied for comparison of categorical variables, whereas ANOVA (Analysis of Variance) was applied for comparison of continuous variables
